Skip to main content
. 2022 Jun 24;81:104102. doi: 10.1016/j.ebiom.2022.104102

Figure 3.

Figure 3

Boxplots of seropositivity rates (%) in pwMS stratified by different anti-CD20 monoclonal antibodies after receiving SARS-CoV-2 vaccine. Each point indicates a study cohort where data were available. Pairwise comparisons are based on the non-parametric Mann-Whitney U independent-samples test (patients with ocrelizumab as reference group). OCR: ocrelizumab, RTX: rituximab, OFA: ofatumumab, NS: not significant (P = 0.91), **: P = 0.0058.